Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

282.42 -1.83 (-0.65%)

Streaming Delayed Price Updated: 11:44 AM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry ↗

April 04, 2025

Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies...

Via Benzinga

Topics Government World Trade

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? ↗

April 03, 2025

Based on a technical and fundamental analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

April 03, 2025

From Insulet Corporation

Via Business Wire

Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks

April 03, 2025

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.

Via StockStory

Topics Artificial Intelligence

What's Driving the Market Sentiment Around Insulet? ↗

February 28, 2025

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

February 24, 2025

Via Benzinga

3 Reasons Investors Love Insulet (PODD)

March 27, 2025

Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and...

Via StockStory

Topics Stocks

Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today ↗

March 21, 2025

Via Benzinga

Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

March 21, 2025

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

Via StockStory

Topics Artificial Intelligence

Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

March 19, 2025

From Insulet Corporation

Via Business Wire

Assessing Insulet: Insights From 6 Financial Analysts ↗

February 21, 2025

Via Benzinga

Insulet Announces Pricing of Senior Notes Due 2033

March 18, 2025

From Insulet Corporation

Via Business Wire

Insulet Announces Proposed Financing Transactions

March 18, 2025

From Insulet Corporation

Via Business Wire

Insulet Expands Omnipod® 5 to Four More International Markets

March 18, 2025

From Insulet Corporation

Via Business Wire

From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes

March 18, 2025

From Insulet Corporation

Via Business Wire

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

March 14, 2025

Via Benzinga

Insulet to Host Investor Day on June 5, 2025

March 11, 2025

From Insulet Corporation

Via Business Wire

Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

March 11, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest...

Via StockStory

Topics Artificial Intelligence

Exploring the Growth Potential of INSULET CORP (NASDAQ:PODD) as It Nears a Breakout. ↗

March 03, 2025

Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?.

Via Chartmill

1 Mid-Cap Stock on Our Watchlist and 2 to Ignore

February 28, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)

February 27, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom...

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are moving on Tuesday? ↗

February 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

February 25, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

February 25, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.

Via Chartmill

Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow

February 24, 2025

Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

Integra LifeSciences (IART) Reports Earnings Tomorrow: What To Expect

February 24, 2025

Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results tomorrow before market hours. Here’s what to look for.

Via StockStory

Curious about which S&P500 stocks are generating unusual volume on Friday? Find out below. ↗

February 21, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Via Chartmill

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst ↗

February 21, 2025

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Via Benzinga

These S&P500 stocks are moving in today's pre-market session ↗

February 21, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Friday?

Via Chartmill

Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations

February 20, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.